ArticlemedRxiv : the preprint server for health sciences2026
Lactoferrin and lysozyme for Kenyan children presenting with wasting and diarrhea: A 2 × 2 factorial randomized controlled trial.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Introduction: Lactoferrin and lysozyme are milk derived proteins with antimicrobial and anti-inflammatory properties. We tested if these supplements improved time-to-nutritional-recovery and reduced the incidence of new moderate or severe diarrhea (MSD) among children presenting to hospital with wasting and diarrhea. Methods: Medically-stable children aged 6-24 months with diarrhea and wasting were randomized to a 16-week course of lactoferrin, lysozyme, a combination of both, or placebo. Time-to-nutritional-recovery (mid-upper arm circumference ≥ 12.5cm) and incidence of new onset MSD were the primary outcomes observed over 6-months follow-up. Subgroup analyses included efficacy by wasting status (severe vs. moderate), stunting, age, inpatient/outpatient, and adherence. Results: Among the 600 children randomized, 531 (88.5%) nutritionally recovered within 16-weeks; 63% among severely wasted children and 95% in children with moderate wasting. The wasting recovery rate in the combination arm was non significantly higher (HR: 1.23, 95%CI: 0.97, 1.57; p=0.083) than the placebo group. Children randomized to lactoferrin alone and lysozyme alone had nutritional recovery rates similar to placebo (HR: 0.94, 95% CI 0.74, 1.20; p=0.607 and HR: 0.91, 95% CI: 0.71, 1.17; p=0.462, respectively). Among severely wasted children, the combination arm had a higher recovery rate than placebo (HR: 2.76, 95% CI 1.49, 5.09; p=0.001), but not the individual lactoferrin (HR: 1.29, 95% CI 0.69, 2.41; p=0.427) and lysozyme (HR: 0.80, 95% CI: 0.40, 1.60; p=0.530) arms. Children randomized to intervention arms had comparable incidence of MSD (82.3-97.0 per 100 child-years) to the placebo arm (75.3 per 100 child-years). Conclusions: The combination of lactoferrin and lysozyme for 16 weeks modestly improved nutritional recovery time particularly among severely wasted children. If confirmed, there may be a role for enteric-targeted therapeutics as adjuvants to severe wasting management. Additional strategies are needed for the post-acute diarrhea recovery period.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.